Search

Your search keyword '"Salvatore Grisanti, Md"' showing total 3 results
Start Over Author "Salvatore Grisanti, Md" Publication Year Range Last 50 years
3 results on '"Salvatore Grisanti, Md"'

1. Management of Severe Cushing Syndrome Induced by Adrenocortical Carcinoma with Abiraterone Acetate: A Case Report

Author

Mélanie Claps, MD, Barbara Lazzari, MD, Salvatore. Grisanti, MD, Vittorio Ferrari, MD, Massimo Terzolo, MD, Sandra Sigala, MD, Sara Vezzoli, MD, Maurizio Memo, MD, Maurizio Castellano, MD, and Alfredo Berruti, MD

Subjects
Diseases of the endocrine glands. Clinical endocrinology, RC648-665
Abstract

ABSTRACT: Objective: Adrenocortical carcinoma (ACC) is a rare disease often associated with hormonal hypersecretion. Hypercortisolism is the most common endocrine syndrome associated with ACC. Abiraterone acetate is a selective and irreversible inhibitor of cytochrome P450 17A1 that is currently used in the treatment of metastatic castration-resistant prostate cancer. The drug induces a profound suppression of both androgen and cortisol secretion and it is a plausible candidate for medical treatment of Cushing's syndrome. We evaluated the hormonal effects of abiraterone administration in a patient with Cushing's syndrome induced by heavily pre-treated metastatic ACC.Methods: A 50-year-old woman with ACC, suffering from severe and unmanageable Cushing's syndrome despite mitotane therapy, received oral abiraterone at 500 mg/day.Results: After 9 days of treatment, the patient experienced a dramatic improvement in autonomy and deambulation, reduction of edema, better control of blood pressure and glycemia, serum potassium normalization, restoration of the sleep-wake rhythm, and disappearance of mental confusion episodes. Hormonal laboratory tests showed a marked reduction in circulating androgen levels and urinary cortisol excretion (urinary free cortisol levels lowered from 1,863 to 520 μg/24 h). Abiraterone therapy was interrupted due to subsequent deterioration of the patient's condition caused by the progression of ACC.Conclusions: Abiraterone can be an effective medical treatment in the management of Cushing's syndrome induced by ACC. This preliminary observation warrants confirmation in a prospective clinical trial.Abbreviations: ACC = adrenocortical carcinoma

Published
2016
Full Text
View/download PDF

2. One-Year Safety and Performance Assessment of the Argus II Retinal Prosthesis: A Postapproval Study

Author

Kim Schaffrath, Md, Hannah Schellhase, Md, Peter Walter, Md, Albert Augustin, Md, Marzio Chizzolini, Md, Bernd Kirchhof, Md, Salvatore Grisanti, Md, Peter Wiedemann, Md, Peter Szurman, Md, Gisbert Richard, Md, Greenberg, Robert J., Phd, Md, Jessy D. Dorn, Phd, Francesco Parmeggiani, Md, and Rizzo, Stanislao

Subjects
Retinal degeneration, Pediatrics, medicine.medical_specialty, Visual acuity, 01 natural sciences, Prosthetics, Visual Prosthesis, Prosthetic vision, NO, 03 medical and health sciences, 0302 clinical medicine, Retinitis pigmentosa, Clinical endpoint, medicine, 0101 mathematics, Adverse effect, Original Investigation, business.industry, Settore MED/30 - MALATTIE APPARATO VISIVO, 010102 general mathematics, medicine.disease, Clinical trial, Ophthalmology, Visual prosthesis, Cohort, 030221 ophthalmology & optometry, Argus II Retinal Prosthesis System, medicine.symptom, business
Abstract

Importance The Argus II Retinal Prosthesis System is indicated for patients with vision loss due to severe to profound outer retinal degeneration, a group with few treatment options. Objectives To collect postapproval safety and visual function data for the Argus II. Design, Setting, and Participants Multicenter, postapproval clinical trial conducted at 9 sites in Germany and Italy. Data were collected from December 2, 2011, to September 30, 2017, and patients were followed-up for 12 months or longer. Patients were 25 years or older with severe to profound outer retinal degeneration, some residual light perception or the ability of the retina to respond to electrical stimulation, and a history of useful form vision and were already planning to undergo Argus II implantation. Main Outcomes and Measures The primary end point of this study was the nature and rate of adverse events. Secondary end points included 3 visual function tests: square localization (SL), direction of motion, and grating visual acuity (GVA). Results Forty-seven patients were followed for 12 months or longer after implant. Mean (SD) age was 56 (12) years, 37 (79%) had retinitis pigmentosa, and 27 (57%) were male. Through the first 12 months postimplantation, 23 patients (49%) experienced 51 nonserious adverse events and 12 (26%) experienced 13 serious adverse events (SAEs), 9 of which were judged to be related to the Argus II, and 4 of which were judged to be related to the procedure. The most common SAE was conjunctival erosion, reported in 4 patients. No significance testing was done for group analysis for the SL or direction-of-motion tests. When averaged across the group, patients’ accuracy on the SL test, but not on the direction-of-motion test, appeared better when the Argus II was on than when it was switched off. For GVA, more patients at each point in time achieved the 2.9 GVA cutoff in the implanted eye when the Argus II was on compared with it switched off. Conclusions and Relevance Safety and visual function outcomes in this clinical practice setting cohort of patients with Argus II implants were consistent with previously reported results. Longer follow-up of these patients and data from additional patients are required to better outline the risks and benefits of this approach to addressing blindness secondary to severe-to-profound outer retinal degeneration. Trial Registration ClinicalTrials.gov identifier:NCT01490827

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results